Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Longeveron announces updated results of ELPIS II, the Company's trial evaluating its stem cell therapy in HLHS.